Fisiopatologia das arritmias cardíacas relacionadas à COVID-19

##plugins.themes.bootstrap3.article.main##

Enzo Gabriel Lacerda Rodrigues
Maria Giovanna da Cruz Tocantins
Luana Kaori Sakaguchi Sakamoto
Eva Ludmila do Socorro da Cruz Marques
João Guilherme Lourenço
Guilherme Henrique Oliveira Moura da Silva
Nayara Letícia da Silva Cruz
Wilsivaldo Viana de Sousa Júnior
Luna Carolina Cardoso Castro
Sérgio Alexandre Oliveira Malcher

Resumo

Objetivos: Identificar na literatura científica a fisiopatologia associada ao desenvolvimento de arritmias em pacientes infectados pelo SARS-CoV-2. Métodos: Revisão integrativa da literatura, com artigos publicados entre 2019 a 2023, nos idiomas português, inglês e espanhol, com texto completo disponível. Utilizou-se como questão norteadora, elaborada conforme a estrutura PICo: “Quais evidências científicas esclarecem a fisiopatologia das arritmias cardíacas causadas pela infecção por SARS-CoV-2 em pacientes adultos?”. A pesquisa seguiu as diretrizes da metodologia Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) adaptada, feita em maio de 2024, sendo realizada buscas nas bases de dados: National Library of Medicine (PubMed) e Biblioteca Virtual em Saúde (BVS), por meio dos Descritores em Ciências da Saúde (DeCS): ”SARS-CoV-2”, “COVID-19”, “Arritmias Cardíacas”/”Arrhythmias, Cardiac”, integrados com o uso dos operadores booleanos “OR” e “AND”. A análise se deu de forma descritiva. Resultados: 11 artigos obedeceram aos critérios de inclusão e exclusão e compuseram a amostra final da pesquisa, em que se evidenciou aspectos biomoleculares associados ao desenvolvimento de arritmias na infecção por SARS-CoV-2. Considerações finais: Identificou-se que fatores inflamatórios e metabólicos favorecem o desenvolvimento de arritmias em pacientes infectados pelo SARS-CoV-2.

##plugins.themes.bootstrap3.article.details##

Como Citar
RodriguesE. G. L., TocantinsM. G. da C., SakamotoL. K. S., MarquesE. L. do S. da C., LourençoJ. G., SilvaG. H. O. M. da, CruzN. L. da S., Sousa JúniorW. V. de, CastroL. C. C., & MalcherS. A. O. (2025). Fisiopatologia das arritmias cardíacas relacionadas à COVID-19. Revista Eletrônica Acervo Saúde, 25(5), e20063. https://doi.org/10.25248/reas.e20063.2025
Seção
Revisão Bibliográfica

Referências

1. BAGNATO G, et al. New-onset atrial fibrillation and early mortality rate in COVID-19 patients: Association with IL-6 serum levels and respiratory distress. Medicina (Kaunas, Lithuania), 2022; 58(4): 530.

2. BI X, et al. Mechanistic insights into inflammation-induced arrhythmias: a simulation study. Frontiers in Physiology, 2022; 13: 843292.

3. BULFAMANTE GP, et al. Evidence of SARS-CoV-2 transcriptional activity in cardiomyocytes of COVID-19 patients without clinical signs of cardiac involvement. Biomedicines, 2020; 8(12): 626.

4. CLEMENS DJ, et al. SARS-CoV-2 spike protein-mediated cardiomyocyte fusion may contribute to increased arrhythmic risk in COVID-19. Plos One, 2023; 18(3): 282151.

5. DENEGRI A, et al. Arrhythmias in COVID-19/SARS-CoV-2 pneumonia infection: prevalence and implication for outcomes. Journal of Clinical Medicine, 2022; 11(5): 1463.

6. DIMAI S, et al. COVID-19-associated cardiomyocyte dysfunction, arrhythmias and the effect of canakinumab. Plos One, 2021; 16(8): 255976.

7. HAN Y, et al. SARS-CoV-2 infection induces ferroptosis of sinoatrial node pacemaker cells. Circulation Research, 2022; 130(7): 963-977.

8. HIKMET F, et al. The protein expression profile of ACE2 in human tissues. Molecular Systems Biology, 2020; 16(7): 9610.

9. HUANG C, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020; 395(10223): 497–506.

10. KELESOGLU S, et al. New onset atrial fibrillation and risk factors in COVID-19. Journal of Electrocardiology, 2021; 65: 76–81.

11. KELESOGLU S, et al. Usefulness of C-reactive protein/albumin ratio as a predictor of new-onset atrial fibrillation in SARS-CoV-2. Biomarkers in Medicine, 2021; 15(13): 1167-1175.

12. LAZZERINI PE, et al. Cardioimmunology of arrhythmias: the role of autoimmune and inflammatory cardiac channelopathies. Nature Reviews Immunology, 2019; 19(1): 63-64.

13. LAZZERINI PE, et al. COVID-19, arrhythmic risk, and inflammation: mind the gap! Circulation, 2020; 142(1): 7-9.

14. LEI X, et al. Activation and evasion of type I interferon responses by SARS-CoV-2. Nature Communications, 2020; 11(1): 3810.

15. LINDNER D, et al. Association of cardiac infection with SARS-CoV-2 in confirmed COVID-19 autopsy cases. JAMA Cardiology, 2020; 5(11): 1281-1285.

16. LIU PP, et al. The science underlying COVID-19: implications for the cardiovascular system. Circulation, 2020; 142(1): 68-78.

17. MARCHIANO S, et al. SARS-CoV-2 infects human pluripotent stem cell-derived cardiomyocytes, impairing electrical and mechanical function. Stem cell reports, 2021; 16(3): 478-492.

18. MEZACHE L, et al. Histologic, viral, and molecular correlates of heart disease in fatal COVID-19. Annals of Diagnostic Pathology, 2022; 60: 151983.

19. MONTEIL V, et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell, 2020; 181(4): 905-9137.

20. MUSIKANTOW DR, et al. Atrial fibrillation in patients hospitalized with COVID-19: incidence, predictors, outcomes and comparison to influenza. Clinical Electrophysiology, 2021; 7(9): 1120-1130.

21. OXFORD. CENTRE FOR EVIDENCE-BASED MEDICINE. 2009. Levels of evidence [Internet]. Disponível em: http ://www.cebm.net/oxfordcentre-evidence-based-medicine-levels-evidencemarch-2009. Acessado em: 26 de maio de 2024.

22. PEREZ-BERMEJO JA, et al. SARS-CoV-2 infection of human iPSC-derived cardiac cells reflects cytopathic features in hearts of patients with COVID-19. Science Translational Medicine, 2021; 13(590): 7872.

23. SCHWARTZ PJ, et al. Inherited cardiac arrhythmias. Nature Reviews Disease Primers, 2020; 6(1): 58.

24. SHANG J, et al. Cell entry mechanisms of SARS-CoV-2. Proceedings of the National Academy of Sciences of the United States of America, 2020; 117(21): 11727–11734.

25. SHARMA, A. et al. Human iPSC-derived cardiomyocytes are susceptible to SARS-CoV-2 infection. Cell Reports Medicine, 2020; 1(4): 100052.

26. SOUZA MT, et al. Integrative review: what is it? How to do it? Einstein (São Paulo). 2010; 8(1): 102-6

27. TORABIZADEH C, et al. Prevalence of cardiovascular complications in coronavirus disease 2019 adult patients: a systematic review and meta-analysis. Iranian Journal of Medical Sciences, 2023; 48(3): 243.

28. TURUGAM MK, et al. Malignant arrhythmias in patients with COVID-19: incidence, mechanisms, and outcomes. Circulation: Arrhythmia and Electrophysiology, 2020; 13(11): 8920.

29. URSI ES. Prevenção de lesões de pele no perioperatório: Revisão integrativa da literatura. Tese de Mestre (Mestrado em Enfermagem) - Escola de Enfermagem de Ribeirão Preto da Universidade de São Paulo, 2005; 48.

30. VARNEY, J. A. et al. COVID-19 and arrhythmia: An overview. Journal of cardiology, 2022; 79(4): 468-475.
31. WÖLFEL R, et al. Virological assessment of hospitalized patients with COVID-2019. Nature, 2020; 581(7809): 465-469.

32. WU L, et al. Atrial inflammation and microvascular thrombogenicity are increased in deceased COVID-19 patients. Cardiovascular Pathology, 2023; 64: 107524.

33. WU L, et al. Atrial inflammation in different atrial fibrillation subtypes and its relation with clinical risk factors. Clinical Research in Cardiology, 2020; 109: 1271-1281.

34. YE Q. The pathogenesis and treatment of the cytokine storm in COVID-19. Journal of Infection, 2020; 80(6): 607-613.

35. YU L, et. al. Cardiac arrhythmia in COVID‐19 patients. Annals of noninvasive electrocardiology, 2024; 29(2): 13105.

36. ZHANG H e DHALLA NS. The role of pro-inflammatory cytokines in the pathogenesis of cardiovascular disease. International journal of molecular sciences, 2024; 25(2): 1082.

37. ZYLLA MM, et al. Predictors and prognostic implications of cardiac arrhythmias in patients hospitalized for COVID-19. Journal of Clinical Medicine, 2021; 10(1): 133.